- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AR-C69931MX | ARL69931 | Kengreal® | Kengrexal®
cangrelor is an approved drug (FDA & EMA (2015))
Compound class: Synthetic organic
Comment: Cangrelor is an intravenously administered antiplatelet compound.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: cangrelor
|No information available.
|Summary of Clinical Use
|In June 2015, cangrelor was apprioved as an adjunct which may be used to prevent the formation of harmful blood clots in the coronary arteries in patients undergoing percutaneous coronary intervention.
|Mechanism Of Action and Pharmacodynamic Effects
|Cangrelor is a P2Y12 inhibitor . Inhibition of P2Y12 reduces ADP-mediated platelet activation and aggregation. This compound has a more rapid onset and reversal of action than currently approved antiplatelet drugs , making it a potentially effective bridging therapy in patients requiring surgical intervention.